• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Precipio Inc. filed SEC Form 8-K: Leadership Update

    1/21/25 4:00:16 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PRPO alert in real time by email
    false 0001043961 0001043961 2025-01-14 2025-01-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D. C. 20549

     

    FORM 8-K

     

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): January 14, 2025

     

    PRECIPIO, INC.
    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware   001-36439   91-1789357
    (State of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

     

    4 Science Park, New Haven, CT 06511

    (Address of principal executive offices) (Zip Code)

     

    (203) 787-7888

    (Registrant's telephone number, including area code)

     

    Not Applicable
    (Former name, former address and former fiscal year, if changed since last report date)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class Ticker symbol(s) Name of each exchange on which
    registered
    Common Stock, $0.01 par value per share PRPO Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

     

    On January 14, 2025 , the Compensation Committee (the “Committee”) of the Board of Directors of Precipio, Inc. (the “Company”) granted certain options (the “Options”) to officers of the Company as part of the Company’s annual long term incentive equity grants, including Ilan Danieli, Ayman Mohamed, Ahmed Zaki Sabet and Matthew Gage (the “Grant”). The Options were granted pursuant to the Company’s Amended & Restated Stock Option and Inventive Plan, as amended and vest in their entirety when the 10-day volume-weighted average price of the Company’s common stock exceeds $30.30 per share, which is five times greater than the option exercise price of $6.06, the closing price of the Company’s common stock on January 14, 2025. If the aforementioned performance is not met, the Options will not vest. The Options are expire on January 14, 2035. The Company granted an aggregate of 34,000 options to the officers of the Company.

     

    The following table sets fort the Options grants to the Company’s names executive officers and Chief Financial Officer:

     

    Name Total Options
    Ilan Danieli 8,000
    Ayman Mohamed 6,000
    Ahmed Zaki Sabet 6,000
    Matthew Gage 4,000

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PRECIPIO, INC.
       
      By: /s/ Ilan Danieli
      Name:   Ilan Danieli
      Title: Chief Executive Officer

     

    Date: January 21, 2025

     

     

    Get the next $PRPO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRPO
    SEC Filings

    See more
    • Precipio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Precipio, Inc. (0001043961) (Filer)

      5/15/25 4:00:44 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Precipio Inc.

      10-Q - Precipio, Inc. (0001043961) (Filer)

      5/14/25 4:50:57 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Precipio, Inc. (0001043961) (Filer)

      5/6/25 4:00:22 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Financials

    Live finance-specific insights

    See more
    • Precipio Announces its Q1-2025 Financial Results

      NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), filed its 10-Q report today. The following are the highlights of the Company's financial performance and outlook for 2025. "We remain confident in the Company's trajectory, supported by strong year-over-year revenue growth, improved gross margins, disciplined cost control and increasing operational efficiency", said Ilan Danieli, Precipio's CEO. "With our expectation of momentum building in our Product business pipeline, as well as the expanded reimbursement opportunities in Pathology Services, we anticipate continued revenue growth and a return to positive operating c

      5/14/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Announces Q1-2025 Shareholder Update Call

      NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2025 corporate update call on May 15th, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio, Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10199645/ff1acc6c66 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questions i

      5/1/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Announces Q4 and year-end 2024 Shareholder Update Call

      NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10197585/fea81a2627 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in su

      3/17/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precipio Announces its Q1-2025 Financial Results

      NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), filed its 10-Q report today. The following are the highlights of the Company's financial performance and outlook for 2025. "We remain confident in the Company's trajectory, supported by strong year-over-year revenue growth, improved gross margins, disciplined cost control and increasing operational efficiency", said Ilan Danieli, Precipio's CEO. "With our expectation of momentum building in our Product business pipeline, as well as the expanded reimbursement opportunities in Pathology Services, we anticipate continued revenue growth and a return to positive operating c

      5/14/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Announces Q1-2025 Shareholder Update Call

      NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2025 corporate update call on May 15th, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio, Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10199645/ff1acc6c66 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questions i

      5/1/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Announces Q4 and year-end 2024 Shareholder Update Call

      NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10197585/fea81a2627 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in su

      3/17/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sandberg Richard A bought $13,986 worth of shares (1,399 units at $10.00) (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      5/30/25 4:31:15 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Sandberg Richard A bought $990 worth of shares (101 units at $9.80) (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      5/28/25 4:37:44 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Sandberg Richard A bought $4,665 worth of shares (500 units at $9.33) (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      5/27/25 4:05:45 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Leadership Updates

    Live Leadership Updates

    See more

    $PRPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $PRPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

      NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib

      3/21/22 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 89bio Announces Appointment of Kathy LaPorte to its Board of Directors

      SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien

      11/3/21 8:00:00 AM ET
      $BOLT
      $ETNB
      $PRPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors

      NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f

      3/3/21 11:00:00 AM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Precipio Inc.

      SC 13G - Precipio, Inc. (0001043961) (Subject)

      8/2/24 2:15:53 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Sandberg Richard A bought $13,986 worth of shares (1,399 units at $10.00) (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      5/30/25 4:31:15 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Sandberg Richard A bought $990 worth of shares (101 units at $9.80) (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      5/28/25 4:37:44 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Sandberg Richard A bought $4,665 worth of shares (500 units at $9.33) (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      5/27/25 4:05:45 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials